Nathan Bennett, MD
Family Medicine · Pittsburgh, PANPI 1992775548
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $326,730 of the $465,001 with a category attached, or 70.3%. AbbVie accounts for 62.6% of it on its own, with 32 other manufacturers making up the rest. Reporting peaked in 2020 at $101,699 and has fallen 66.1% since, to $34,428 in 2025. Among family medicine clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,167 payments — averaging $398.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$291K
- Amgen$54K
- Teva Pharmaceuticals USA, Inc.$31K
- Impel Pharmaceuticals Inc.$29K
- Novartis$20K
- Biohaven Pharmaceuticals, Inc.$12K
- plus $28K from 27 others
Across 433 payments — averaging $2598.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$319K
- Amgen$310K
- Eli Lilly$123K
- Ipsen Innovation$75K
- Biohaven Pharmaceutical Holding Company Ltd.$61K
- H. Lundbeck A S$57K
- plus $180K from 6 others
What the payments were for
- Consulting fees$90,78720%
- Speaking & faculty fees$326,73070%
- Travel & lodging$25,1295%
- Food & beverage$21,7265%
- Education$2800%
- Other$3490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 543 | $291,317 |
| Amgen | 131 | $53,566 |
| Teva Pharmaceuticals USA, Inc. | 99 | $31,219 |
| Impel Pharmaceuticals Inc. | 20 | $28,657 |
| Novartis | 34 | $20,091 |
| Biohaven Pharmaceuticals, Inc. | 38 | $11,786 |
| Biohaven Pharmaceutical Holding Company Ltd. | 53 | $11,478 |
| Pfizer | 73 | $6,688 |
| Axsome Therapeutics, Inc. | 3 | $2,066 |
| H. Lundbeck A S | 2 | $1,850 |
| Promius Pharma LLC | 6 | $1,267 |
| Avanir Pharmaceuticals, Inc. | 12 | $926 |
| Novo Nordisk | 55 | $875 |
| Lilly USA, LLC | 16 | $652 |
| Ipsen Innovation | 2 | $472 |
| Lundbeck LLC | 13 | $448 |
| GSK | 22 | $363 |
| Eko Health, Inc. | 1 | $349 |
| Bayer | 10 | $252 |
| UCB, Inc. | 4 | $137 |
| Abbott | 5 | $104 |
| Upsher-smith Laboratories LLC | 3 | $74 |
| Supernus Pharmaceuticals, Inc. | 5 | $68 |
| AstraZeneca | 4 | $62 |
| Phathom Pharmaceuticals, Inc. | 3 | $62 |
| Collegium Pharmaceutical, Inc. | 2 | $42 |
| Amneal Pharmaceuticals LLC | 2 | $29 |
| Almatica Pharma LLC | 1 | $21 |
| Boehringer Ingelheim | 1 | $20 |
| Alkermes, Inc. | 1 | $18 |
| Tonix Medicines, Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Nestle Healthcare Nutrition Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$465,001 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 66 | $68,435 |
| Aimovig AutoinjectorErenumab-Aooe | 75 | $66,463 |
| EliquisApixaban | 61 | $63,537 |
| FarxigaDapagliflozin Propanediol | 53 | $48,599 |
| Emgality PenGalcanezumab-Gnlm | 47 | $48,228 |
| OzempicSemaglutide | 37 | $46,173 |
| Nurtec OdtRimegepant Sulfate | 24 | $43,541 |
| BotoxOnabotulinumtoxina | 33 | $40,685 |
| QuliptaAtogepant | 38 | $40,438 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $31,660 |
| TrulicityDulaglutide | 30 | $31,613 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 37 | $30,981 |
| RybelsusSemaglutide | 11 | $19,460 |
| MounjaroTirzepatide | 15 | $15,940 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 32 | $12,816 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Nurtec Odt | $6,688 | $107,07885 claims |
| AbbVieBotox, Qulipta, Linzess | $291,317 | $93,08485 claims |
| Boehringer IngelheimJardiance | $20 | $68,43566 claims |
| Novo NordiskOzempic, Rybelsus | $875 | $65,63348 claims |
| AstraZenecaFarxiga | $62 | $48,59953 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $652 | $47,55245 claims |
| GSKTrelegy Ellipta, Shingrix | $363 | $35,90567 claims |
| Upsher-smith Laboratories LLCTopiramate | $74 | $1,176122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Pittsburgh
- Deborah GilboaPittsburgh$60K
- Gregory JaffePittsburgh$38K
- Neil SkolnikJenkintown$904K
- Lisa EspinozaNew Hope$722K
- Christopher Varacallodu Bois$627K
- Paul DoghramjiCollegeville$617K
- Brian DeyarminBethel Park$491K
- Gary OwensGlen Mills$404K
- Mary ZakutneyIrwin$393K
- H WilkinsSellersville$380K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.